BOTHELL, Wash., Jan. 23, 2018 /PRNewswire/ -- BioLife
Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer
and marketer of proprietary clinical grade biopreservation media
("BioLife" or the "Company"), today announced that its joint
venture partner SAVSU Technologies ("SAVSU") will supply SAVSU
smart precision shipping containers throughout the World Courier
network. SAVSU designs and manufactures innovative high-performance
cloud-connected passive storage and transport containers optimized
for the cell and gene therapy supply chain. World Courier is the
global leader in specialty logistics and a part of
AmerisourceBergen.
The combination of World Courier's global logistics network and
SAVSU's patent pending, enhanced temperature-controlled evo DV4
& DV10 liquid nitrogen (LN2) shippers will enable cell and gene
therapy developers to more efficiently and effectively move
critical biologic shipments at cryogenic temperatures worldwide,
with enhanced visibility and shipment monitoring capabilities.
The addition of these shippers to World Courier's packaging
fleet connects therapy developers to the latest cold chain
technologies, and offers a greater choice of options for cryogenic
shipping. This extends World Courier's track record of developing
and verifying the latest technology through its Climate
Optimisation Research and Engineering (CORE) Labs, to provide its
customers with access to a wide range of market-leading packaging
solutions.
The combination of World Courier and evo LN2 dry vapor shippers
offer significant value to cell and gene therapy developers by
providing:
- Short lead times, enabled by SAVSU's rapid charging and
availability throughout World Courier's 140+ owned office global
network
- High quality and extended temperature performance, underpinned
by the transformative design of evo smart shippers and world-class
specialty logistics capabilities of World Courier
- Low cost profile as a result of reduced shipper weight and
dimensions
- Real time data visibility and traceability through the evo.is
SaaS dashboard, amplified into actionable information by the global
reach of World Courier to intervene and remediate if required
- Seamless integration of shipping container supply and
logistics, coupled with full vein-to-vein traceability for
customers through integration with cell orchestration
platforms
Bruce McCormick, President and
CTO of SAVSU, commented that "by partnering with World Courier, we
are now able to provide customers with a new level of service and
peace of mind for their personalized medicine and other biologic
shipments, on a global scale."
World Courier is working to realize the full potential of cell
and gene therapies for both patients and manufacturers. At
the same time, the company aims to improve supply chain performance
for the global healthcare market by providing more reliable and
cost-effective clinical trial and commercial product
transport. For more information please visit
https://www.worldcourier.com/insights-events/market-insights/detail/savsu-dry-shippers.
Due to the expanded marketing reach of World Courier, and to
eliminate potential channel conflict, BioLife and SAVSU have agreed
to terminate the marketing services agreement originally entered
into between the companies on December
31, 2016. In exchange, BioLife's equity ownership in
SAVSU, previously scheduled to be reduced to 25% on December 31, 2019, has now been fixed at 35%,
before taking into account any additional capital contributions
made after December 31, 2016.
Mike Rice, BioLife Solutions CEO,
commented, "The alliance between World Courier and SAVSU is an
endorsement of the best in class technologies we have developed
over the past three years. This is a critical inflection point in
the cell therapy market, as awareness of the critical need for
better cold chain technologies for personalized medicine has never
been greater."
About BioLife Solutions
BioLife Solutions develops, manufactures and markets
biopreservation media products and smart shipping containers
connected to a cloud hosted cold chain management app to improve
the quality of delivery logistics for cells, tissues, and organs.
The Company's proprietary HypoThermosol® and CryoStor® platform of
solutions are highly valued in the regenerative medicine,
biobanking, and drug discovery markets. BioLife's biopreservation
media products are serum-free and protein-free, fully defined, and
are formulated to reduce preservation-induced cell damage and
death. BioLife's enabling technology provides commercial companies
and clinical researchers significant improvement in shelf life and
post-preservation viability and function of cells, tissues, and
organs. For more information please visit www.biolifesolutions.com
and follow BioLife on Twitter.
Except for historical information contained herein, this
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements include, but are not limited to,
statements concerning the company's anticipated business and
operations, guidance for financial results in 2018, the potential
utility of and market for its products and services, potential
revenue growth and market expansion, regulatory approvals and/or
commercial manufacturing of our customers' products, and potential
customer revenue. All statements other than statements of
historical fact are statements that could be deemed forward-looking
statements. These statements are based on management's current
expectations and beliefs and are subject to a number of risks,
uncertainties and assumptions that could cause actual results to
differ materially from those described in the forward-looking
statements, including among other things, uncertainty regarding
market adoption of products; uncertainty regarding third-party
market projections; market volatility; competition; litigation; and
those other factors described in our risk factors set forth in our
filings with the Securities and Exchange Commission from time to
time, including our Annual Report on Form 10-K and Quarterly
Reports on Form 10-Q. We undertake no obligation to update the
forward-looking statements contained herein or to reflect events or
circumstances occurring after the date hereof, other than as may be
required by applicable law.
Media &
Investor Relations
|
|
|
Roderick de
Greef
|
|
|
Chief Financial
Officer
|
|
|
(425)
686-6003
|
|
|
rdegreef@biolifesolutions.com
|
|
|
|
|
|
View original content with
multimedia:http://www.prnewswire.com/news-releases/biolife-solutions-announces-savsu-alliance-with-world-courier-300586675.html
SOURCE BioLife Solutions, Inc.